
Opinion|Videos|September 30, 2024
Treatment of Bio-Naïve Patients or Those Progressing on Topical or Biologic Atopic Dermatitis Therapy
Key Takeaways
- Bio-naïve patients with moderate atopic dermatitis often start with topical corticosteroids or calcineurin inhibitors as first-line treatments.
- Disease progression on topical treatments may necessitate systemic therapies or phototherapy to achieve better disease control.
Focusing on clinical scenarios, experts on atopic dermatitis discuss how their treatment approaches vary depending on patient-specific factors.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How would you treat:
- A bio naïve patient with moderate atopic dermatitis?
- A patient whose disease is continuing to progress on topical treatments?
- Patient progressing on biologic therapy
Advertisement
Related to this article

Stephan Weidinger, MD, PhD, discusses 5-year ADlong data showing durable skin clearance and itch control with lebrikizumab in atopic dermatitis.

Children aged 2 - 11 with atopic dermatitis saw early, lasting itch and sleep gains with nemolizumab through 1 year in phase 2 data shared at PeDRA 2026.

Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.

A roundup of updates spanning PsO, atopic dermatitis, alopecia areata, vitiligo, palmoplantar pustulosis, cutaneous sarcoidosis, and discoid lupus.

In ADtouch, lebrikizumab improved clearance, itch, and pain in hand and foot atopic dermatitis. Shawn Kwatra, MD, discusses what the data mean.
Advertisement
Advertisement
Trending on HCPLive
1
I-124 Evuzamitide PET/CT Highly Sensitive, Specific in Amyloid Detection
2
CHEST 2026: Day 1 Recap — 5 Headlines to Know
3
VERDICT Links Vedolizumab Disease Clearance to Fewer UC Complications
4
Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD
5

